Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P2SI
|
|||
| Former ID |
DNCL002477
|
|||
| Drug Name |
Galiximab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Lymphoma [ICD-11: 2A80-2A86; ICD-9: 202.8, 208.9] | Phase 2 | [1] | |
| Company |
Biogen Idec
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00516217) Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma. U.S. National Institutes of Health. | |||
| REF 2 | Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol. 2005 Jul 1;23(19):4390-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.